Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx Group (MDXG) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to 19.51%.

  • Mimedx Group's EBITDA Margin rose 623.00% to 19.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.69%, marking a year-over-year decrease of 477.00%. This contributed to the annual value of 16.87% for FY2024, which is 533.00% up from last year.
  • Mimedx Group's EBITDA Margin amounted to 19.51% in Q3 2025, which was up 55.54% from 12.55% recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's EBITDA Margin registered a high of 26.89% during Q2 2024, and its lowest value of -15.79% during Q1 2022.
  • Its 3-year average for EBITDA Margin is 13.94%, with a median of 13.34% in 2023.
  • Per our database at Business Quant, Mimedx Group's EBITDA Margin skyrocketed by 2,775bps in 2023 and then tumbled by 1,435bps in 2025.
  • Quarterly analysis of 5 years shows Mimedx Group's EBITDA Margin stood at 2.53% in 2021, then surged by 1,268bps to 15.21% in 2022, then soared by 263bps to 17.84% in 2023, then slumped by 594bps to 11.90% in 2024, then spiked by 623bps to 19.51% in 2025.
  • Its EBITDA Margin was 19.51% in Q3 2025, compared to 12.55% in Q2 2025 and 9.35% in Q1 2025.